SWK Holdings Corp
NASDAQ:SWKH
SWK Holdings Corp
Interest Income Expense
SWK Holdings Corp
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SWK Holdings Corp
NASDAQ:SWKH
|
Interest Income Expense
$4.5m
|
CAGR 3-Years
33%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
LM Funding America Inc
NASDAQ:LMFA
|
Interest Income Expense
$9m
|
CAGR 3-Years
143%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A-Mark Precious Metals Inc
NASDAQ:AMRK
|
Interest Income Expense
$3.8m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
5%
|
CAGR 10-Years
11%
|
|
|
FlexShopper Inc
NASDAQ:FPAY
|
Interest Income Expense
-$21.3m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
California First Leasing Corp
OTC:CFNB
|
Interest Income Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Standard Premium Finance Holdings Inc
OTC:SPFX
|
Interest Income Expense
-$3.8m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
SWK Holdings Corp
Glance View
SWK Holdings Corp. is engaged in the business of financial and asset management in the field of pharmaceutical. The company is headquartered in Dallas, Texas and currently employs 35 full-time employees. The firm is focused on providing various capital solutions to a range of life science companies, institutions and inventors. The firm operates through two segments: Finance Receivables and Pharmaceutical Development. Its Finance Receivables segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. In addition, through its wholly owned subsidiary, SWK Advisors LLC, it provides non-discretionary investment advisory services to institutional clients in separately managed accounts to similarly invest in life science finance. Through its subsidiary, Enteris BioPharma, Inc., its Pharmaceutical Development segment offers formulation solutions built around its oral drug delivery technology, the Peptelligence platform.
See Also
What is SWK Holdings Corp's Interest Income Expense?
Interest Income Expense
4.5m
USD
Based on the financial report for Dec 31, 2024, SWK Holdings Corp's Interest Income Expense amounts to 4.5m USD.
What is SWK Holdings Corp's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
19%
Over the last year, the Interest Income Expense growth was 2%. The average annual Interest Income Expense growth rates for SWK Holdings Corp have been 33% over the past three years , 19% over the past five years .
You don't have any saved screeners yet